The long, tormented regulatory journey Heron Therapeutics Inc. has been on over the past nearly seven years with its chemotherapy-induced nausea and vomiting (CINV) drug Sustol (granisetron) has finally come to a somewhat successful end, with the FDA granting its go-ahead for the product to be marketed in the US, although not for the broad use the company had sought.
The product moves Heron from a research and development company to a commercial enterprise. The question now is whether Heron...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?